
## Thomas R Dilling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2257413/publications.pdf Version: 2024-02-01



THOMAS P DULING

#	Article	IF	CITATIONS
1	Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Research, 2018, 78, 1820-1832.	0.9	69
2	Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect. Theranostics, 2020, 10, 567-584.	10.0	63
3	Exploring Structural Parameters for Pretargeting Radioligand Optimization. Journal of Medicinal Chemistry, 2017, 60, 8201-8217.	6.4	52
4	HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight, 2021, 6, .	5.0	40
5	Bioorthogonal Masking of Circulating Antibody–TCO Groups Using Tetrazine-Functionalized Dextran Polymers. Bioconjugate Chemistry, 2018, 29, 538-545.	3.6	35
6	Noninvasive <sup>89</sup> Zr-Transferrin PET Shows Improved Tumor Targeting Compared with <sup>18</sup> F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. Journal of Nuclear Medicine, 2018, 59, 51-57.	5.0	31
7	Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue. Nuclear Medicine and Biology, 2020, 84-85, 63-72.	0.6	16
8	A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 166-176.	7.0	14
9	Polyazamacrocycle Ligands Facilitate <sup>89</sup> Zr Radiochemistry and Yield <sup>89</sup> Zr Complexes with Remarkable Stability. Inorganic Chemistry, 2020, 59, 17473-17487.	4.0	13
10	ERK Inhibition Improves Anti–PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2021, 20, 2026-2034.	4.1	10
11	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. Journal of Experimental Medicine, 2021, 218, .	8.5	9